^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316, SHR1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    6d
    Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    carboplatin • paclitaxel • AiRuiLi (adebrelimab)
    7d
    A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=400, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)
    15d
    Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=249, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • docetaxel • albumin-bound paclitaxel • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    15d
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=120 --> 160
    Enrollment open • Enrollment change
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • AiRuiLi (adebrelimab) • HRS-4642 • garetatug rezetecan (SHR-A1904)
    17d
    HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    17d
    SOP-XH-IRB: Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=118, Not yet recruiting, Fujian Medical University
    New P3 trial
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    20d
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy (clinicaltrials.gov)
    P2, N=66, Recruiting, Shandong Tumor Hospital
    New P2 trial
    |
    irinotecan • famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    28d
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    30d
    A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • AiRuiLi (adebrelimab) • SHR-7367
    30d
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=400, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    1m
    SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC (clinicaltrials.gov)
    P2, N=208, Recruiting, Shandong Provincial Hospital
    New P2 trial
    |
    capecitabine • oxaliplatin • AiRuiLi (adebrelimab)